Bayer Prolactin Receptor Antibody For Male And Female Pattern Hair Loss

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
Hopemedicines intention was to do a international multi centre phase 2 in US/EU/AUS (I don’t know why) . But since Australia rejected them to bypass phase 1 they will have to complete phase 1 in Australia and then commence with the original plan . They must be doing it to save costs down the line. We basically got set back 1 year cause of this

if you would like to bring HMI-115 to Market and you got a rejection in Australia and First had to do a Phase I Trial there… would you do the Phase I Trial in Australia or would you do Phase II in US and Europe to bring the product to Market as soon as possible????

it Really is to stupid For me to beliebe this fu.cking sh1t
 

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
Why is f***.ing Australia that important For them??? It Makes absolutely No sense. If they did the First trial in China i would understand it because the company is pur of China. It would be mich fastet then. But Australia?! Wtf
 

coolio

Experienced Member
My Regimen
Reaction score
547
if this treatment is not as effective as it seems, let's get ready for another generation thrown away
I feel the same way except I still have faith in MOOGENE Medi, STEMSON Tx , and dNOVO

I've been surfing baldness forums since the early 2000s. Trust me, there are always a few groups out there working on something. Multiple treatments were in development 15-20 years ago. None of it means sh*t unless they are getting results.

This prolactin receptor antibody is the most promising thing I've seen in a long time. It's also the only thing that looks promising right now. If it doesn't work then IMO we are probably staying bald until the 2030s.
 
Last edited:

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984

The application for the second clinical trial of HMI-115, the first new monoclonal antibody drug, for androgen loss has been approved by the US FDA. Release Date: 2022-01-27 Views: 160 Recently,

Hope Medicine Inc., a biomedical valley company in Jiangbei New Area region ( Heqirui Pharmaceuticals (hereinafter referred to as Heqirui), a science-based clinical innovation biopharmaceutical company, announced its first new drug of monoclonal antibody HMI-115, which is of global interest and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of endometriosis II in 2021. Following the Phased Trial (IND) clinical trial, her application for a Phase II clinical trial (IND) for the treatment of Androgen hair loss (Androgenetic Alopecia) also recently approved by the US FDA. In April 2019, Heqirui Pharmaceuticals and Bayer AG signed a global exclusive license agreement for the development and industrialization of HMI-115, a monoclonal antibody targeting a prolactin receptor (PRLR). It is being developed and industrialized by Heqirui Pharmaceutical to develop and industrialize a number of indications around the world. This antibody has demonstrated excellent properties in animal models including non-human primate (NHP) models and human safety. Its treatment of two major indications, endometriosis and androgen alopecia, has been approved by the US FDA for a second stage clinical trial. The second stage clinical trial of HMI-115 in endometriosis started in late 2021 in the United States. The Phase Two Clinical Trial for the Treatment of Androgen Allopecia is an international, multi-center, randomized, double-blind, placebo-controlled study to be conducted in the United States, Australia and other countries. Dr., CEO of Chery Pharmaceuticals Henri Nico Doods said: "The FDA approved the IND of the second indication of HMI-115 and I am proud of the company which is an important milestone for young startups like Heqirui. This is an important step towards our vision to bring a new drug and highly differentiated products to patients around the world Patients with two main indications of endometriosis and hair loss look forward to new treatments with better efficacy and safety To be able to receive two IND approvals in such a short time, is a great incentive for the Heqirui team.We will continue to strengthen and expand global clinical research and development activities and strive to bring more innovative drug treatment options to patients around the world.
 

trialAcc

Senior Member
My Regimen
Reaction score
1,531
if you would like to bring HMI-115 to Market and you got a rejection in Australia and First had to do a Phase I Trial there… would you do the Phase I Trial in Australia or would you do Phase II in US and Europe to bring the product to Market as soon as possible????

it Really is to stupid For me to beliebe this fu.cking sh1t
You realize that they can still launch a P2 trial in the USA or EU right? There is no press release with this Aus trial, meaning they probably have other things ready to launch/announce before they start issuing the final press release.
 

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
You realize that they can still launch a P2 trial in the USA or EU right? There is no press release with this Aus trial, meaning they probably have other things ready to launch/announce before they start issuing the final press release.

i Hope you Are Right. But i am very nervous… it Doesnt make Sense to start Phase I and immediately After this starting a Phase II Trial in other countries.

It would make Sense:

Option 1: to do Phase I and wait until Trial finished. After then checken the results and think about If it is Worth to start Phase II.

Option 2: to start Phase II in US directly
 

trialAcc

Senior Member
My Regimen
Reaction score
1,531
i Hope you Are Right. But i am very nervous… it Doesnt make Sense to start Phase I and immediately After this starting a Phase II Trial in other countries.

It would make Sense:

Option 1: to do Phase I and wait until Trial finished. After then checken the results and think about If it is Worth to start Phase II.

Option 2: to start Phase II in US directly
They are not doing a phase 1 to check if it's worth it, no one does that. Phase 1 is generally 100% safety related.

They're doing a phase 1/2 because Australia clearly declined to allow a P2 to start in their country without data for that dose level or on men at all.
 

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
They are not doing a phase 1 to check if it's worth it, no one does that. Phase 1 is generally 100% safety related.

They're doing a phase 1/2 because Australia clearly declined to allow a P2 to start in their country without data for that dose level or on men at all.

yes But Why they start this Australia Trial at First?

they had FDA clearance in US For Phase II Trial! Why Arent they faster in starting the Trial in US then starting in Australia?
 

trialAcc

Senior Member
My Regimen
Reaction score
1,531
yes But Why they start this Australia Trial at First?

they had FDA clearance in US For Phase II Trial! Why Arent they faster in starting the Trial in US then starting in Australia?
Should email the company* and ask. Obviously Australia is an important market for them as they aren't even doing trials in China yet despite almost guaranteed clearance.
 
Last edited:

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
Should email the company* and ask. Obviously Australia is an important market for them as they aren't even doing trials in China yet despite almost guaranteed clearance.
I wrote a lot of e mails to the company and got No answers
 

HMI 115 IS THE CURE dude

Member
My Regimen
Reaction score
24
I wrote a lot of e mails to the company and got No answers

Advantages of clinical trial in Australia :

“Cost – In comparison to US and Europe, Australia is 30% lower in study budgets. If R&D tax incentives are applicable, the cost advantage climbs to over 50%.

Incentives – Australia has the highest tax incentive for medical research and clinical trials in the world. Australia offers a generous 43.5% cash refund for clinical trials conducted in Australia if the applying country has a global revenue of less than 20M AUD.

Investigational New Drug (IND) not a pre-requisite – One of the major advantages of conducting clinical trials in Australia is that there is no need for an approved US FDA IND for initiating clinical studies. Clinical studies can be initiated in Australia at any time before or during the IND application process and then the data from these studies supplemented to the application, thus leading to a tremendous advantage of saved time. We have witnessed companies advancing directly in to Phase II at the time of IND approval since all Phase I studies were completed in Australia by the time IND approval was secured. This has been possible due to confidence in the very high quality of data generated for clinical studies in Australia.
 

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
Advantages of clinical trial in Australia :

“Cost – In comparison to US and Europe, Australia is 30% lower in study budgets. If R&D tax incentives are applicable, the cost advantage climbs to over 50%.

Incentives – Australia has the highest tax incentive for medical research and clinical trials in the world. Australia offers a generous 43.5% cash refund for clinical trials conducted in Australia if the applying country has a global revenue of less than 20M AUD.

Investigational New Drug (IND) not a pre-requisite – One of the major advantages of conducting clinical trials in Australia is that there is no need for an approved US FDA IND for initiating clinical studies. Clinical studies can be initiated in Australia at any time before or during the IND application process and then the data from these studies supplemented to the application, thus leading to a tremendous advantage of saved time. We have witnessed companies advancing directly in to Phase II at the time of IND approval since all Phase I studies were completed in Australia by the time IND approval was secured. This has been possible due to confidence in the very high quality of data generated for clinical studies in Australia.
But in this case hope Medicine has IND Approval For Phase II studies in US. So they should move in this fuc.king Phase II Trial as planned
 

trialAcc

Senior Member
My Regimen
Reaction score
1,531

Zon Ama

Established Member
My Regimen
Reaction score
149
Any news on that? Will it be announced when there are enough people for the trials in Australia?
 

ppma

Member
Reaction score
23
If the trial renders positive results, just hoping that the next step towards market goes through the mRNA pathway. Creating monoclonal antibodies is a expensive process, but the antibody sequence could be translated into mRNA for its production inside the body.

(https) pubmed.ncbi.nlm.nih.gov/30795778/
 

RolfLeeBuckler

Experienced Member
My Regimen
Reaction score
984
If the trial renders positive results, just hoping that the next step towards market goes through the mRNA pathway. Creating monoclonal antibodies is a expensive process, but the antibody sequence could be translated into mRNA for its production inside the body.

(https) pubmed.ncbi.nlm.nih.gov/30795778/
So in the mRNA pathway When the product could be commercialized?
 

ppma

Member
Reaction score
23
So in the mRNA pathway When the product could be commercialized?
Couldn't tell really, but if the monoclonal antibody demonstrates efficacy (phase 3), then the mRNA version should undergo all the testing and trial phases since it would be a different product... Realistically, I guess that we would all be slick bald when a supposed release of an mRNA BAY/HMI-115 reached the market.

My wish concerns only money and logistics only.
 
Top